Figure 1. Mature miR-150 expression is low in myeloid leukemia cells.

Mature miR-150 expression is decreased in CML and AML cell lines and in primary patient CD34+ progenitor cells from healthy individuals, BC CML and AML samples relative to average miR-150 expression in normal bone marrow (NBM). (A) MiR-150 expression is low or absent in BC CML (K562, LAMA84, and Kcl-22) and AML (HL60, NB4, KG1, PL21, MV4-11, and THP-1) cell lines. Expression is shown as a fold-change relative to miR-150 expression in NBM on a log₁₀ scale as determined by QPCR (performed in duplicate). (B) By QPCR, miR-150 expression was decreased in CD34+ sorted (n=6) vs. unsorted (n=5) NBM. In primary BC CML (n=10) and adult AML (n=22) patient samples, miR-150 expression was significantly decreased compared to unsorted NBM, but not sorted CD34+ NBM. Individual patient samples are shown as fold-change relative to miR-150 expression in NBM on a log₁₀ scale, with means indicated by bars (*P≤0.05, **P≤0.001 for comparisons, Student’s t-test). (C) MiR-150 expression was obtained by RNA sequencing for 182 pediatric AML cases and was stratified by risk group based on cytogenetic and molecular abnormalities. Expression is on a log₂ scale, with averages indicated by bars (Student’s t-test used for comparisons).